On April 25, 2024 Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, reported that, based on the strength of the science and its relevance, VIRAGE – the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) – has been accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held in Chicago, IL, from May 31-June 4 (Press release, Theriva Biologics, APR 25, 2024, View Source [SID1234642361]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ASCO Presentation Details
Title: VIRAGE: A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Presenter: Dr. Rocío García-Carbonero
Session Title: Poster Session – Gastrointestinal Cancer: Gastroesophageal, Pancreatic, and Hepatobiliary
Poster Session Date and Time: 01 June 2024, 1:30 PM-4:30 PM US CDT
Abstract Number: TPS4210